| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 1, 2023 |
| Accession Number: | 0001193125-23-286282 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies Company (NYSE:SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company's common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") on July 7, 2023, under the existing symbol "SQZ" and new CUSIP number
Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023 SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent portfolio updates. "The confirmed complete response in our first patient in the AAC trial has brought enthusiasm to our trial sites, and we are encouraged by the positive momentum for e
A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort Strong enrollment rates; Anticipate initial clinical data from the highest-dose cohort in the fourth quarter of 2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The co
Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company's Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chemistry, Manufacturing and Controls; Translational Research; and Engineering SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Howard Bernstein, M.D., Ph.D., has been appointed to the company's board of directors, effective October 31, 2022. Dr. Bernstein has served as the company's Chief Scientific Officer since July 2015, a
Experienced Biotech Leader and Capital Markets Professional Elevated to Chief Financial Officer from Chief Business Officer Role Appointment Effective July 11, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Micah Zajic, as the company's Chief Financial Officer, effective immediately. Mr. Zajic has served as the company's Chief Business Officer since October 2020 and brings nearly 20 years of biotechnology and capital markets experience to the role. As CFO, Mr. Zajic will continue to report to the CEO and will lead the company's finance and accounting, business development,
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease Appointment Effective June 1st, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer. Dr. Warren will report to the CEO and lead the company's clinical development, clinical operations, translational medicine, and regulatory affairs functions. Marshelle has tremendous experience in cell-based therapeutic development and will provide complementary expertise as we seek to rapidly advan
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
Patient's Clinical, Radiographic and Histologic Results Support Potential Impact of SQZ Investigational Therapeutic Patient Demonstrated Symptomatic Improvement Radiographic Response Observed in Target Lesion Tumor Conversion from Desert to Inflamed Phenotype with 8-Fold Increase in CD8 T Cell Tumor Infiltration and 50-Fold Increase in Tumor PD-L1 Expression Interim Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and Investigational Therapy was Generally Well Tolerated Company to Host Conference Call Today at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented
Interim SQZ-PBMC-HPV Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and that Therapy was Generally Well Tolerated Oral Presentation at ESMO Immuno-Oncology Congress on December 9 to Focus on Highest-Dose Monotherapy Cohort of SQZ™ APC Candidate Company to Host Conference Call on December 9 at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced interim results from the highest-dose monotherapy cohort of its ongoing Phase 1/2 clinical trial of SQZ-PBMC-HPV, an investigational cell therapy being evaluated in certain patients with advanced or metastatic Human Papillomavirus
DEFM14A - SQZ Biotechnologies Co (0001604477) (Filer)
PREM14A - SQZ Biotechnologies Co (0001604477) (Filer)
15-12G - SQZ Biotechnologies Co (0001604477) (Filer)